Focused On-demand Library for Thioredoxin-related transmembrane protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y320

UPID:

TMX2_HUMAN

Alternative names:

Cell proliferation-inducing gene 26 protein; Thioredoxin domain-containing protein 14

Alternative UPACC:

Q9Y320; B7Z4R4; Q53G73; Q561W0; Q5J7Q7; Q8NBP9; Q9H3L1

Background:

Thioredoxin-related transmembrane protein 2, also known as Cell proliferation-inducing gene 26 protein and Thioredoxin domain-containing protein 14, plays a pivotal role in cellular processes. It functions as a regulator of the cellular redox state, influencing protein post-translational modification, protein folding, and mitochondrial activity. This protein indirectly regulates neuronal proliferation, migration, and organization during brain development.

Therapeutic significance:

The protein is linked to a neurodevelopmental disorder characterized by microcephaly, cortical malformations, and spasticity. This association highlights its potential as a target for therapeutic intervention in treating or managing this debilitating condition.